New Application Report showcases TRPM8 assay with reliable, temperature-sensitive pharmacology
Our latest application report demonstrates a robust TRPM8 assay using HEK293 cells on all three automated patch clamp (APC) platforms: QPatch Compact, QPatch, and Qube 384. The assay reliably measures both inward and outward TRPM8 currents, and shows clear, temperature-dependent modulation by known activators and antagonists.
Temperature-dependent TRPM8 pharmacology on Sophion APC systems
In this TRPM8 assay, activation by racemic menthol and icilin produced concentration-response relationships, with potency increasing at the lower test temperature (18 °C, versus 27 °C). Conversely, the TRPM8 blocker capsazepine produced concentration-dependent inhibition with minimal change in potency between those temperatures. These findings support the use of Sophion’s medium- and high-throughput systems for TRPM8 pharmacology and early drug discovery.
TRPM8 assay on Sophion APC platforms: methods and key readouts
- Stable TRPM8 expression in HEK293 cells
- Standard extracellular and K-gluconate intracellular solutions
- A 100 ms voltage ramp from -80 mV to +80 mV
- Analysis of outward current at +50 mV and inward current at -50 mV
- Temperature-dependence of activators but not capsazepine block at 27 °C and 18 °C
- Cumulative and non-cumulative concentration-response curves
- EC50 and IC50 values were determined
Representative traces and concentration-response curves illustrate assay stability, reproducibility and comparability to literature values, making this a transferable protocol for laboratories planning TRPM8 screening campaigns.
Why adopt this TRPM8 assay in your workflow
If your project targets thermosensation, cold allodynia or TRPM8-related indications (e.g. certain cancers, ocular and bladder disorders), this assay provides: a validated APC workflow; temperature-controlled activation that mirrors physiological sensitivity; and throughput options suited to both detailed pharmacology and screening.